BioSpace News Archive

Junshi Biosciences, a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced the completion of study subjects enrollment in Phase I trial of SARS-CoV-2 neutralizing monoclonal antibody injection, developed jointly with Institute of Microbiology, Chinese Academy of Sciences.

Junshi Biosciences announced that following its application to The Stock Exchange of Hong Kong Limited pursuant to Rule 18A.12 of the Rules Governing the Listing of Securities on HKEX, HKEX has granted approval for the dis-application of Rules 18A.09 to 18A.11 of the Listing Rules.

In lieu of an in-person update to the media, Dr. Howard Njoo, Canada’s Deputy Chief Public Health Officer, issued the following statement on behalf of Dr. Theresa Tam, Canada’s Chief Public Health Officer.

All five participants in the 5x1011 vg/kg and 1×1012 vg/kg dose cohorts and seven participants in the 2×1012 vg/kg dose show an acceptable safety profile, stable and durable factor VIII expression and substantial improvement in annualized bleed rate (ABR) after between two and 3.3 years follow-up

The Data Demonstrating Benefits of Pharmacokinetic-Guided Prophylaxis Therapy in Hemophilia and von Willebrand Disease are Among 13 Presentations from Takeda’s Hematology Portfolio and Pipeline

Data from two Phase 2 randomized, placebo-controlled, dose-ranging studies using ciraparantag demonstrate efficacy and safety in the reversal of apixaban and rivaroxaban

BeiGene, Ltd., a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, announced the pricing of a registered direct offering of 145,838,979 ordinary shares, par value $0.0001 per share, to certain existing investors.

Amgen announced an additional investment of approximately $421 million in BeiGene’s registered direct offering of ordinary shares, which maintains Amgen’s current pro rata ownership of BeiGene at approximately 20.3%.